{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"ORR is a key secondary efficacy endpoint with overall response defined as best response of CR, CRi, PR, or PRwL, according to the modified IWCLL/IWG Response Criteria, with modification for treatment-related lymphocytosis as defined in the protocol.","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"},{"description":"Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.","id":"OG001","title":"Ofatumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent to Treat","reportingStatus":"POSTED","timeFrame":"Until disease progression or unacceptable toxicity assessed up to 6 years","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}